DemeRx appoints ibogaine expert to advisory board

DemeRx strengthens advisory board with ibogaine expert

DemeRx, a company focused on developing treatments for addiction, has announced the appointment of Juan Sanchez-Ramos to its scientific advisory board. Sanchez-Ramos is recognized for his pioneering work in ibogaine research, a psychoactive compound being studied for its potential in treating opioid use disorder and other conditions.

Juan Sanchez-Ramos' role and expertise

Juan Sanchez-Ramos brings significant expertise to DemeRx, particularly in the field of ibogaine research. His work has been instrumental in advancing the understanding of ibogaine's effects and its potential therapeutic applications. By joining DemeRx, Sanchez-Ramos is expected to contribute to the company's efforts in developing innovative treatments for addiction.

Why it matters

The inclusion of a leading expert like Sanchez-Ramos on DemeRx's advisory board underscores the company's commitment to advancing ibogaine research. As the opioid crisis continues to pose a significant public health challenge, exploring new treatment avenues is crucial. Sanchez-Ramos' involvement could accelerate the development of ibogaine-based therapies, potentially offering new hope for individuals struggling with addiction.

DemeRx's strategic move to bolster its scientific advisory board with experienced researchers highlights the growing interest in alternative treatments for addiction.